How do you pay?
Which strength?
How many capsules?

How to pay the least

From

$11.42 for 30 capsules delivered ($6.17 plus $5.25 shipping)

Generic fenofibrate from Cost Plus Drugs, by mail. Pick the strength on your label for its own price.

What to do

  1. Make a free account on costplusdrugs.com. Ask your prescriber to send the prescription there, or Cost Plus Drugs can transfer it.Open Cost Plus Drugs 
  2. Order generic fenofibrate. It comes by mail.

Other ways

Need it today? From $14.26 for 30 capsules with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.

See the price and get the card 

Every company’s fenofibrate is rated by the FDA to work the same, so any pharmacy can fill your prescription with the one it stocks.

See every pharmacy’s price

Where to buy it

Pharmacies’ own cash prices for generic fenofibrate, lowest first.

Pick up in storeDelivered

From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.

About these prices

Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.

Who makes it

8 companies sell fenofibrate in this form, each one rated by the FDA as a substitute for the others. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

  • Ajanta Pharma67 mg, 134 mg, 200 mg

    Has lactose · Has dyes: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40

    Product page on ajantapharmausa.com

    How it looks, what’s in it, NDCs

    67 mg Pink, capsule, 14 mm, marked “ap / FEN67”

    PackageNDC
    Bottle of 10027241-118-04
    Bottle of 50027241-118-05

    134 mg Blue, capsule, 18 mm, marked “ap / FEN134”

    PackageNDC
    Bottle of 10027241-119-04
    Bottle of 50027241-119-05

    200 mg Orange, capsule, 21 mm, marked “ap / FEN200”

    PackageNDC
    Bottle of 10027241-120-04
    Bottle of 50027241-120-05

    Inactive ingredients: crospovidone, povidone k25, lactose monohydrate, magnesium stearate, starch, corn, sodium lauryl sulfate, croscarmellose sodium, talc, shellac, propylene glycol, ferrosoferric oxide, potassium hydroxide, D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, titanium dioxide, ferric oxide yellow

    FDA label

  • Alembic Pharmaceuticals67 mg, 134 mg, 200 mg

    Has dyes: D&C Yellow No. 10, FD&C Yellow No. 6, D&C Red No. 28, FD&C Red No. 40

    How it looks, what’s in it, NDCs

    67 mg Opaque pale yellow, capsule, 16 mm, marked “A317”

    PackageNDC
    Bottle of 3062332-084-30
    Bottle of 10062332-084-31
    Bottle of 50062332-084-71

    134 mg Opaque white, capsule, 19 mm, marked “A318”

    PackageNDC
    Bottle of 3062332-085-30
    Bottle of 10062332-085-31
    Bottle of 50062332-085-71

    200 mg Opaque orange, capsule, 19 mm, marked “A319”

    PackageNDC
    Bottle of 3062332-086-30
    Bottle of 10062332-086-31
    Bottle of 50062332-086-71

    Inactive ingredients: microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, magnesium stearate, titanium dioxide, gelatin, FD&C Yellow No. 6, D&C Yellow No. 10, shellac, ferrosoferric oxide, potassium hydroxide, D&C Red No. 28, FD&C Red No. 40

    FDA label

  • ANI Pharmaceuticals67 mg, 134 mg, 200 mg

    Has lactose · Has dyes: D&C Red No. 33, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red No. 3

    Product page on anipharmaceuticals.com

    How it looks, what’s in it, NDCs

    67 mg Opaque Purple Cap and Body, capsule, 14 mm, marked “AMG / 444”

    PackageNDC
    Bottle of 10043975-444-10

    134 mg Opaque Blue Cap and Body, capsule, 18 mm, marked “AMG / 445”

    PackageNDC
    Bottle of 10043975-305-10
    Bottle of 50043975-305-50

    200 mg Opaque Orange Cap and Body, capsule, 19 mm, marked “AMG / 446”

    PackageNDC
    Bottle of 10043975-306-10
    Bottle of 50043975-306-50

    Inactive ingredients: silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone k30, starch, corn, sodium lauryl sulfate, talc, titanium dioxide, gelatin, FD&C Blue No. 1, D&C Red No. 33, D&C Yellow No. 10, shellac, propylene glycol, ferrosoferric oxide, potassium hydroxide, crospovidone (35 .mu.m), FD&C Red No. 3, ferric oxide red, ferric oxide yellow

    FDA label

  • Apotex43 mg, 130 mg

    Has dyes: D&C Yellow No. 10, FD&C Blue No. 2

    How it looks, what’s in it, NDCs

    43 mg White and LIGHT GREEN, capsule, 14 mm, marked “APO / F43”

    PackageNDC
    Bottle of 3060505-3120-3
    Bottle of 10060505-3120-1

    130 mg White and DARK GREEN, capsule, 19 mm, marked “APO / F130”

    PackageNDC
    Bottle of 3060505-3121-3
    Bottle of 9060505-3121-9
    Bottle of 10060505-3121-1
    Bottle of 50060505-3121-5

    Inactive ingredients: silicon dioxide, crospovidone (120 .mu.m), sodium lauryl sulfate, gelatin, titanium dioxide, D&C Yellow No. 10, FD&C Blue No. 2, shellac, ferrosoferric oxide, propylene glycol, ammonia

    FDA label

  • Aurobindo Pharma67 mg, 134 mg, 200 mg

    Has dyes: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40

    Product page on aurobindousa.com

    How it looks, what’s in it, NDCs

    67 mg Pink, capsule, 14 mm, marked “FBT / 67”

    PackageNDC
    Bottle of 10059651-201-01

    134 mg Light Blue, capsule, 17 mm, marked “FBT / 134”

    PackageNDC
    Bottle of 10059651-202-01

    200 mg Orange, capsule, 19 mm, marked “FBT / 200”

    PackageNDC
    Bottle of 10059651-203-01

    Inactive ingredients: silicon dioxide, croscarmellose sodium, D&C Red No. 28, gelatin, magnesium stearate, microcrystalline cellulose, poloxamer 407, povidone k25, sodium lauryl sulfate, titanium dioxide, FD&C Blue No. 1, FD&C Red No. 40, ferrosoferric oxide, potassium hydroxide, shellac, ferric oxide yellow

    FDA label

  • Chartwell RX67 mg, 134 mg, 200 mg

    Has lactose · Has dyes: FD&C Blue No. 1, FD&C Red No. 3

    How it looks, what’s in it, NDCs

    67 mg Opaque cap and opaque body, capsule, 16 mm, marked “CE / 89”

    PackageNDC
    Bottle of 9062135-893-90

    134 mg Opaque cap and opaque body, capsule, 18 mm, marked “CE / 225”

    PackageNDC
    Bottle of 9062135-894-90

    200 mg Opaque cap and opaque body, capsule, 19 mm, marked “CE / 27”

    PackageNDC
    Bottle of 9062135-899-90

    Inactive ingredients: lactose monohydrate, crospovidone, starch, corn, povidone, sodium lauryl sulfate, magnesium stearate, gelatin, titanium dioxide, FD&C Blue No. 1, FD&C Red No. 3, shellac, propylene glycol, ferrosoferric oxide, potassium hydroxide

    FDA label

  • Glenmark Pharmaceuticals67 mg, 134 mg, 200 mg

    Has lactose · Has dyes: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40

    Product page on glenmarkpharma-us.com

    How it looks, what’s in it, NDCs

    67 mg Opaque pink cap and body, capsule, 14 mm, marked “G / 580”

    PackageNDC
    Bottle of 10068462-580-01

    134 mg Opaque light blue cap and body, capsule, 18 mm, marked “G / 581”

    PackageNDC
    Bottle of 10068462-581-01

    200 mg Opaque orange cap and body, capsule, 19 mm, marked “G / 582”

    PackageNDC
    Bottle of 10068462-582-01

    Inactive ingredients: silicon dioxide, crospovidone (35 .mu.m), lactose monohydrate, magnesium stearate, povidone k30, starch, corn, sodium lauryl sulfate, talc, D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, titanium dioxide, gelatin, ferrosoferric oxide, potassium hydroxide, shellac, ferric oxide yellow

    FDA label

  • Torrent Pharmaceuticals67 mg, 134 mg, 200 mg

    Has lactose · Has dyes: FD&C Blue No. 1, FD&C Red No. 40

    How it looks, what’s in it, NDCs

    67 mg Opaque, capsule, 14 mm, marked “1440 / 67”

    PackageNDC
    Bottle of 9013668-440-90
    Bottle of 10013668-440-01
    Bottle of 50013668-440-05

    134 mg Opaque light, capsule, 18 mm, marked “1439 / 134”

    PackageNDC
    Bottle of 9013668-439-90
    Bottle of 10013668-439-01
    Bottle of 50013668-439-05

    200 mg Opaque, capsule, 21 mm, marked “1438 / 200”

    PackageNDC
    Bottle of 9013668-438-90
    Bottle of 10013668-438-01
    Bottle of 50013668-438-05

    Inactive ingredients: crospovidone, FD&C Blue No. 1, FD&C Red No. 40, ferric oxide red, ferric oxide yellow, ferrosoferric oxide, gelatin, lactose monohydrate, magnesium stearate, polyethylene glycol 3350, potassium hydroxide, propylene glycol, shellac, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate, starch, pregelatinized corn, titanium dioxide

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What to say at the pharmacy

“Before you fill it, what would I pay for generic fenofibrate?”

Paying cash? Ask for the cash price. With insurance, ask what your plan charges.

What it’s used for

What the FDA label says

Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS).

C = cholesterolTG = triglyceridesLDL = low density lipoproteinVLDL = very low density lipoproteinIDL = intermediate density lipoprotein

Lipid Elevation

Type · Lipoprotein Elevated · Major · Minor

I (rare) · chylomicrons · TG · ↑ ↔ C

IIa · LDL · C · —

IIb · LDL, VLDL · C · TG

III (rare) · IDL · C, TG · —

IV · VLDL · TG · ↑ ↔ C

V (rare) · chylomicrons, VLDL · TG · ↑ ↔

a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease)b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L)c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment

Definite Athlerosclerotic Diseasea · Two or More Other Risk Factorsb · LDL-Cholesterol mg/dL (mmol/L)

Initiation Level · Goal

No · No · ≥ 190 (≥ 4.9) · < 160 (< 4.1)

No · Yes · ≥ 160 (≥ 4.1) · < 130 (< 3.4)

Yes · Yes or No · ≥ 130c (≥ 3.4) · < 100 (< 2.6)

Source: the FDA label for Fenofibrate (Aurobindo Pharma Limited), September 8, 2021. Full label on DailyMed 

Good to know

  • Different companies’ fenofibrate can look different. The FDA requires each to work the same way.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.